IL136303A - History -5 (-2 Imidazolinylamino) - Banimidazole, preparation and use as an α-adororeceptor agonists - Google Patents

History -5 (-2 Imidazolinylamino) - Banimidazole, preparation and use as an α-adororeceptor agonists

Info

Publication number
IL136303A
IL136303A IL13630398A IL13630398A IL136303A IL 136303 A IL136303 A IL 136303A IL 13630398 A IL13630398 A IL 13630398A IL 13630398 A IL13630398 A IL 13630398A IL 136303 A IL136303 A IL 136303A
Authority
IL
Israel
Prior art keywords
methyl
hydrogen
dosage range
cyano
compound
Prior art date
Application number
IL13630398A
Other languages
English (en)
Hebrew (he)
Other versions
IL136303A0 (en
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of IL136303A0 publication Critical patent/IL136303A0/xx
Publication of IL136303A publication Critical patent/IL136303A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL13630398A 1997-11-24 1998-11-20 History -5 (-2 Imidazolinylamino) - Banimidazole, preparation and use as an α-adororeceptor agonists IL136303A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6676797P 1997-11-24 1997-11-24
US6670097P 1997-11-25 1997-11-25
PCT/US1998/024694 WO1999026942A1 (en) 1997-11-24 1998-11-20 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability

Publications (2)

Publication Number Publication Date
IL136303A0 IL136303A0 (en) 2001-05-20
IL136303A true IL136303A (en) 2004-02-08

Family

ID=26747058

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13630398A IL136303A (en) 1997-11-24 1998-11-20 History -5 (-2 Imidazolinylamino) - Banimidazole, preparation and use as an α-adororeceptor agonists

Country Status (23)

Country Link
US (1) US6486190B1 (ko)
EP (1) EP1037887B1 (ko)
JP (1) JP2001524478A (ko)
KR (1) KR20010032435A (ko)
CN (1) CN1284073A (ko)
AT (1) ATE271048T1 (ko)
BR (1) BR9815017A (ko)
CA (1) CA2311344C (ko)
CO (1) CO4970802A1 (ko)
DE (1) DE69825075T2 (ko)
ES (1) ES2223143T3 (ko)
HU (1) HUP0101469A3 (ko)
IL (1) IL136303A (ko)
IN (1) IN190809B (ko)
NO (1) NO20002655L (ko)
NZ (1) NZ504707A (ko)
PE (1) PE133699A1 (ko)
PL (1) PL340711A1 (ko)
RU (1) RU2193562C2 (ko)
SK (1) SK7792000A3 (ko)
TR (1) TR200002242T2 (ko)
TW (1) TW505642B (ko)
WO (1) WO1999026942A1 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1385823E (pt) 2001-04-09 2007-01-31 Novartis Vaccines & Diagnostic Compostos de guanidino como agonistas do receptor de melanocortina-4 (r-mc4)
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
KR101053816B1 (ko) * 2003-02-20 2011-08-03 론자 아게 N-치환된 포름아미드의 제조 방법
US20040167194A1 (en) * 2003-02-20 2004-08-26 Randall Jared Lynn Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
BRPI0511519A (pt) * 2004-05-25 2007-12-26 Sansrosa Pharmaceutical Dev In método para tratar ou prevenir um distúrbio inflamatório da pele e os sintomas associados com ele, composição tópica adequada para tratar ou evitar os sintomas de um distúrbio inflamatório dermatológico, e, embalagem para uma composição tópica
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
CA2865593A1 (en) * 2012-02-27 2013-09-06 Eye Therapies Llc Compositions and methods for the treatment of migraine
WO2015073736A1 (en) 2013-11-13 2015-05-21 Arbor Pharmaceuticals, Llc Methods and compositions for treating adhd
AU2016365219A1 (en) * 2015-11-30 2018-07-05 Novus Therapeutics, Inc. Compositions and methods for otologic prophylaxis and treatment
EA030197B1 (ru) * 2016-03-22 2018-07-31 Общество С Ограниченной Ответственностью "Рубикон" Таблетированная форма противовирусного лекарственного средства
JP7163014B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 感冒薬

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4036976A (en) 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
US4217356A (en) 1975-08-22 1980-08-12 Sandoz Ltd. 2-Imidazolinylamino-2,1,3-benzothiadiazoles
US4398028A (en) 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
EP0025269B1 (en) 1979-08-23 1985-11-13 Beecham Group Plc Anti-diarrhoea veterinary composition
EP0047328B1 (de) 1980-09-05 1984-05-09 Siegfried Aktiengesellschaft 1H- und 2H-Indazolderivate und diese enthaltendes Arzneimittel
FR2638356A1 (fr) 1988-10-28 1990-05-04 Anben Nouveaux derives de la 2-arylimino-imidazolidine pour diminuer la pression intra-oculaire et traiter le glaucome
US5180721A (en) 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5281591A (en) 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5231096A (en) 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
EP0775134A4 (en) 1994-08-04 1997-08-13 Synaptic Pharma Corp NEW BENZIMIDAZOLE DERIVATIVES
ID24081A (id) * 1997-04-15 2000-07-06 Procter & Gamble Senyawa-senyawa 5-(2-imidazolinilamino) benzimidazol yang berguna sebagai agonis-agonis alfa-2-adrenoseptor

Also Published As

Publication number Publication date
HUP0101469A2 (hu) 2001-10-28
ATE271048T1 (de) 2004-07-15
JP2001524478A (ja) 2001-12-04
IN190809B (ko) 2003-08-23
TR200002242T2 (tr) 2000-11-21
US6486190B1 (en) 2002-11-26
NO20002655D0 (no) 2000-05-24
IL136303A0 (en) 2001-05-20
KR20010032435A (ko) 2001-04-25
BR9815017A (pt) 2001-09-11
SK7792000A3 (en) 2001-01-18
EP1037887A1 (en) 2000-09-27
CN1284073A (zh) 2001-02-14
WO1999026942A1 (en) 1999-06-03
NO20002655L (no) 2000-07-24
HUP0101469A3 (en) 2003-01-28
EP1037887B1 (en) 2004-07-14
CA2311344C (en) 2006-02-07
CO4970802A1 (es) 2000-11-07
DE69825075T2 (de) 2005-08-25
PL340711A1 (en) 2001-02-26
DE69825075D1 (de) 2004-08-19
WO1999026942A8 (en) 2000-08-03
CA2311344A1 (en) 1999-06-03
NZ504707A (en) 2002-11-26
RU2193562C2 (ru) 2002-11-27
ES2223143T3 (es) 2005-02-16
PE133699A1 (es) 2000-03-05
TW505642B (en) 2002-10-11

Similar Documents

Publication Publication Date Title
US5541210A (en) 5-(2-imidazolinylamino)benzimidazole compounds useful as alpha-2 andrenoceptor agonists
US6117871A (en) 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US6395764B1 (en) 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agnonists
AU730369B2 (en) Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
US5965595A (en) 2-Imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
EP1037887B1 (en) 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
US5804587A (en) 6-(2-imidazolinylamino) quinolines useful as alpha-2 adrenoceptor agonists
US5916900A (en) 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
AU736992B2 (en) 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists
US5914342A (en) 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
US6436978B1 (en) Guanidinylamino heterocycle compounds useful as α-2 adrenoceptor agonists
CA2285610A1 (en) 5-(2-imidazolinylamino)benzimidazole compounds useful as alpha-2 adrenoceptor agonists
AU741774B2 (en) 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
AU5433998A (en) 2-imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonis ts
WO1998023612A1 (en) 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists
EP0944601A1 (en) Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
CZ20001912A3 (cs) 5-(2-Imidazolinylamino)-benzimidazolové deriváty, jejich příprava a jejich použití jako alfa adrenoceptorové agonisty se zlepšenou metabolickou stálostí
MXPA00005120A (en) 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha. -adrenoceptor agonists with improved metabolic stability

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees